GKOS vs. MDLN: Glaukos vs. Medline Stock Comparison

Company Profile

Glaukos (GKOS) and Medline (MDLN) both belong to the Health Care Equipment & Supplies industry, though GKOS is classified under Health Care Equipment while MDLN falls under Health Care Supplies.

Glaukos (GKOS) has been public since June 25, 2015 with a meaningfully longer listed history, while Medline (MDLN) only listed on December 17, 2025 — long-window metrics on the MDLN side should be interpreted with caution.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Medline (MDLN) reports a negative beta of -0.93, suggesting inverse market sensitivity over the measurement window. That is uncommon for ordinary equities and can reflect commodity-linked or hedge-like exposure, but it can also come from statistical noise. Glaukos (GKOS) has a non-negative beta of 0.68.

Risk-Adjusted Performance

Risk-Return Positioning

Both GKOS and MDLN need 1-year volatility and 1-year return to plot risk-return positioning.

Risk-Adjusted Metrics

Profitability

Glaukos (GKOS) reports a negative ROE of -22.84%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Medline (MDLN) reports 4.85%, ranking against industry peers normally.

Glaukos (GKOS) reports a negative net margin of -24.60%, usually indicating a net loss over the period. Meanwhile Medline (MDLN) reports 1.85%, ranking against industry peers normally.

Both Glaukos (GKOS) at 0.39% and Medline (MDLN) at 5.22% run core operations about as efficiently as their industries’ norm — neither stands out on operating profitability.

Profitability Metrics

Growth

Only one side can be read here: Glaukos (GKOS) reports revenue growth of 32.33%, ranked against its industry; Medline (MDLN) has no revenue growth figure this period.

Only one side can be read here: Medline (MDLN) reports EPS growth of 117.38%, ranked against its industry; Glaukos (GKOS) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Both Glaukos (GKOS) at 4.57 and Medline (MDLN) at 4.04 post current ratio above their industries’ typical mid-ranges — short-term liquidity appears comfortable, though unusually high readings can point to idle current assets.

Glaukos (GKOS) at 0.15 keeps leverage in the lower industry quartile, while Medline (MDLN) at 0.65 runs a more typical debt-to-equity mix.

Financial Strength Metrics

Dividends

Neither Glaukos (GKOS) nor Medline (MDLN) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither Glaukos (GKOS) nor Medline (MDLN) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: Medline (MDLN) trades at 90.09 times trailing earnings, ranked against its peers, while Glaukos (GKOS) has no P/E ratio this period.

Medline (MDLN) at 1.70 prices around its industry’s typical P/S ratio, while Glaukos (GKOS) at 19.24 clears its benchmark range — GKOS looks notably rich on sales.

Medline (MDLN) at 2.95 sits near its industry’s typical P/B ratio, while Glaukos (GKOS) at 18.51 prices above its benchmark range — GKOS looks rich relative to book.

Valuation Metrics